The Selective WEE1 Inhibitor Azenosertib Shows

Time: 2:15 pm
day: Day Two Track B PM


• Combination of Azenosertib, a novel, selective, WEE1 inhibitor, with KRAS G12C inhibitors demonstrates synergistic anticancer activity in vitro and in vivo

• The combination drives regression and extends duration of response in KRAS G12C mutant tumor models of NSCLC, CRC, and PDAC

• The combination overcomes innate and acquired resistance to KRAS G12C inhibition